Drug name - Daurismo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(8 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

CN101687841A PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

CN101687841B PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

IN288288B PFIZER A Compound That Is 1-[(2R,4R)-2-(1Hbenzimidazol- 2-Yl)- 1-Methyl-Piperidin- 4-Yl]-3-(4- Cyanophenyl)Urea Or A Pharmaceutically Acceptable Salt Thereof
Jun, 2028

(5 years from now)

IN200908059P1 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP2170860A2 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP2170860B9 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP2170860B1 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP3666768A1 PFIZER Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1)
Apr, 2036

(13 years from now)

EP3666768B1 PFIZER Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1)
Apr, 2036

(13 years from now)

EP3286176B1 PFIZER Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Apr, 2036

(13 years from now)

EP3286176A1 PFIZER Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives Jun, 2028

(5 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate Apr, 2036

(13 years from now)

Drugs and Companies using GLASDEGIB MALEATE ingredient

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.